Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Rifkin on Split Dosing of Daratumumab in Myeloma

January 4th 2019

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

Dr. Parekh on the Mechanism of Action of Selinexor in Myeloma

January 4th 2019

Samir Parekh, MD, associate professor of Medicine, Mount Sinai Health System, discusses the mechanism of action of selinexor in multiple myeloma.

Despite Progress With CAR T-Cell Therapy, Transplant Retains Role in Myeloma

January 3rd 2019

Deepu Madduri, MD, discusses the status of transplant for eligible patients and the developments that are being made with CAR T-cell therapy in multiple myeloma.

Classes of Immunotherapy Under Investigation in Multiple Myeloma

December 27th 2018

Hearn Jay Cho, MD, PhD, discusses classes of immunotherapy under investigation in multiple myeloma.

Dr. Jagannath on Cancer Proliferation in Multiple Myeloma

December 21st 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses cancer proliferation in multiple myeloma.

Relapsed/Refractory Myeloma Landscape Slated to Expand

December 20th 2018

Samir Parekh, MD, discusses the excitement of selinexor and venetoclax (Venclexta) as possible additions to the myeloma treatment landscape

Dr. Chari on PVd for Relapsed Patients With Multiple Myeloma

December 18th 2018

Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.

Jagannath Discusses Building on the Biology of Multiple Myeloma

December 17th 2018

Sundar Jagannath, MD, provides insight into the biology of multiple myeloma.

Dr. Cho on the Knowledge Deficit in Multiple Myeloma

December 15th 2018

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the knowledge deficit in multiple myeloma.

Expert Evaluates Evolving Options in Relapsed/Refractory Myeloma

December 14th 2018

Ajai Chari, MD, discusses some of the available and anticipated combinations for use in patients with relapsed/refractory multiple myeloma.

Dr. Siegel on Distinguishing Between Classes of Drugs in Myeloma

December 14th 2018

David M. Siegel, MD, PhD, chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses a trial distinguishing between classes of drugs in myeloma.

Landgren Explains Crucial Role of MRD in Myeloma

December 13th 2018

C. Ola Landgren, MD, PhD, discusses the role of minimal residual disease negativity and the emergence of CAR T-cell therapy in multiple myeloma.

BiTE Antibodies Show Encouraging Activity in Myeloma, AML

December 11th 2018

Data from 2 early-stage trials of bispecific T-cell engager antibody constructs in relapsed/refractory hematologic malignancies demonstrated antitumor activity and early evidence of tolerability.

Dr. Madduri on Treatment After CAR T Cells in Myeloma

December 11th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses treatment after CAR T-cell therapy in patients with myeloma.

Robust Future Ahead for Stem Cell Transplants

December 6th 2018

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

Dr. Chari Discusses Carfilzomib Dosing in Myeloma

December 5th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses carfilzomib (Kyprolis) dosing in the treatment of patients with multiple myeloma.

Competition Grows in Anti-BCMA CAR Pipeline for Multiple Myeloma

December 5th 2018

A multitude of BCMA-targeted CAR T-cell therapies are currently in development, each demonstrating different efficacy and safety profiles and each with different constructs.

Dr. Martin on MRD Status in Multiple Myeloma

December 4th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses minimal residual disease (MRD) status in multiple myeloma.

Daratumumab Plus Rd New Frontline Standard in Transplant-Ineligible Myeloma

December 4th 2018

The triplet of daratumumab, lenalidomide, and dexamethasone reduced the risk of disease progression or death by 44% compared with lenalidomide plus dexamethasone in newly diagnosed patients with multiple myeloma who were not candidates for high-dose chemotherapy and autologous stem-cell transplant.

Selinexor Induces Responses in a Quarter of Patients with Heavily Pretreated MM

December 4th 2018

A Selinexor combination regimen induced an overall response rate of 26.2% in heavily pretreated patients with penta-refractory multiple myeloma.